Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1638-1645

  Choi, Doo Ho ^a   Lee, Min Hyuk ^a   Dale, Allen E ^a   Carter, Darryl ^a   Haffty, Bruce G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PROTEIN P53; DNA;

ADULT; ARTICLE; BLOOD ANALYSIS; BREAST CARCINOMA; CANCER GENETICS; CANCER PATIENT; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; KOREA; LYMPHOCYTE; MISSENSE MUTATION; ONCOGENE; OVARY CANCER; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CARCINOMA; CROSS-SECTIONAL STUDY; ETHNOLOGY; GENETICS; NUCLEOTIDE SEQUENCE; ONSET AGE; PEDIGREE; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADULT; AGE OF ONSET; BREAST NEOPLASMS; CARCINOMA; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; IMMUNOHISTOCHEMISTRY; KOREA; MUTATION, MISSENSE; PEDIGREE; POLYMERASE CHAIN REACTION;

EID: 2442650570     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.179     Document Type: Article

References (49)

1. Greenlee RT, Murray T. Bolden S. et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000
2. Korean Ministry of Health and Welfare: Annual report of the central cancer registry in Korea. Seoul, Korea. Ministry of Health and Welfare, 2000
3. Miller BA, Kolonel LN, Bernstein L: Racial/ethnic patterns of cancer in the United States, 1988-1992. Bethesda, MD, National Cancer Institute, 1996
4. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994
5. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995
6. Robson M, Gilewski T, Haas B, et al: BRCA-associated breast cancer in young women. J Clin Oncol 16:1642-1649, 1998
7. Garber J: Inherited breast cancer: Increasingly familiar territory. J Clin Oncol 16:1639-1641, 1998
8. Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457-1462, 1995
9. Abeliovich D, Kaduri L, Lerer I, et al: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505-514, 1997
10. Neuhausen S, Gilewski T, Norton L, et al: Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 13:126-128, 1996
11. Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al: High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 56:3663-3665, 1996
12. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al: Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60:1079-1084, 1997
13. Krainer M, Silva-Arrieta S, Fitzgerald MG, et al: Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 336:1416-1421, 1997
14. Langston AA, Malone KE, Thompson JD, et al: BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 334:137-142, 1996
15. Malone KE, Daling JR, Neal C, et al: Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88:1393-1402, 2000
16. Anton-Culver H, Cohen PF, Gildea ME, et al: Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 36:1200-1208, 2000
17. Peto J, Collins N, Barfoot R, et al: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943-949, 1999
18. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases: Anglian Breast Cancer Study Group. Br J Cancer 83:1301-1308, 2000
19. Papelard H, de Bock GH, van Eijk R, et al: Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer 83:719-724, 2000
20. Loman N, Johannsson O, Kristoffersson U, et al: Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93:1215-1223, 2001
21. Southey MC, Tesoriero AA, Andersen CR, et al: BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer 79:34-39, 1999
22. Chang J, Hilsenbeck SG, Sng JH, et al: Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res 7:1739-1742, 2001
23. De Leon Matsuda ML, Liede A, Kwan E, et al: BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer 98:596-603, 2002
24. Couch FJ. DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409-1415, 1997
25. Struewing JP, Hange P. Wacholder S, et al: The risk of cancer associated with specific mutations of BRCAI and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997
26. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998
27. Unger MA, Nathanson KL, Calzone K, et al: Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67:841-850, 2000
28. Eng C, Brody LC, Wagner TM, et al: Interpreting epidemiological research: Blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 38:824-833, 2001
29. Yang Q, Khoury MJ, Rodriguez C, et al: Family history score as a predictor of breast cancer mortality: Prospective data from the Cancer Prevention Study II, United States, 1982-1991. Am J Epidemiol 147:652-659, 1998
30. Devilee P: BRCA1 and BRCA2 testing: Weighing the demand against the benefits. Am J Hum Genet 64:943-948, 1999
31. Willett W: The search for the causes of breast and colon cancer. Nature 338:389-394, 1989
32. Lichtenstein P, Holm NV, Verkasalo PK, et al: Environmental and heritable factors in the causation of cancer: Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78-85, 2000
33. Lamartiniere CA, Cotroneo MS, Fritz WA, et al: Genistein chemoprevention: Timing and mechanisms of action in murine mammary and prostate. J Nutr 132:552-558, 2002
34. Lu LJ, Anderson KE, Grady JJ, et al: Decreased ovarian hormones during a soya diet: Implications for breast cancer prevention. Cancer Res 60:4112-4121, 2000
35. Fodor FH, Weston A, Bleiweiss IJ, et al: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63:45-51, 1998
36. Kang HC, Kim IJ, Park JH, et al: Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Hum Mutat 20:235-240, 2002
37. Ford D, Easton DF. Bishop DT, et al: Risks of cancer in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Lancet 343:692-695, 1994
38. Oddoux C, Struewing JP, Clayton CM, et al: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14:188-190, 1996
39. Ramus SJ, Friedman LS, Gayther SA, et al: A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nat Genet 15:14-15, 1997
40. Friedman E, Bar-Sade Bruchim R, Kruglikova A. et al: Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet 63:1224-1227, 1998
41. Liede A, Rehal P, Vesprini D, et al: A breast cancer patient of Scottish descent with germline mutations in BRCA1 and BRCA2. Am J Hum Genet 62:1543-1544, 1998
42. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002
43. Shapiro MB, Senapathy P: RNA splice junctions of different classes of eukaryotes: Sequence statistics and functional implications in gene expression. Nucleic Acids Res 15:7155-7174, 1987
44. Huyton T, Bates PA, Zhang X, et al: The BRCA1 C-terminal domain: Structure and function. Mutat Res 460:319-332, 2000
45. Vallon-Christersson J, Cayanan C, Haraldsson K, et al: Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10:353-360, 2001
46. Johannsson OT, Idvall I, Anderson C, et al: Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33:362-371, 1997
47. Crook T, Grassland S, Crompton MR, et al: p53 mutations in BRCA1-associated familial breast cancer. Lancet 350:638-639, 1997
48. Armes JE, Egan AJ, Southey MC, et al: The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study. Cancer 83: 2335-2345, 1998
49. Xu X, Qiao W, Linke SP, et al: Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 28:266-271, 2001